Nanobody-drug conjugates hijack the human vitamin B12 uptake route
A major challenge in cancer therapy is selectively targeting cancer cells over healthy ones. A recent study by the Locher group (IMBB) describes the development of camelid single-domain antibodies (nanobodies) that selectively ...
Feb 28, 2022
0
46